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Abstract
Background Speckle tracking echocardiography (STE) is
an echocardiography modality that is able to measure left
ventricular (LV) characteristics, including rotation, strain
and strain rate. Strain measures myocardial fibre contrac-
tion and relaxation. This study aims to assess the effect of
renal sympathetic denervation (RDN) on functional
myocardial parameters, including STE, and to identify
potential differences between responders and non-
responders.
Methods The study population consisted of 31 consecutive
patients undergoing RDN in the context of treatment for
resistant hypertension. Patients were included between
December 2012 and June 2014. Transthoracic echocar-
diography and speckle tracking analysis was performed at
baseline and at 6 months follow-up.
Results The study population consisted of 31 patients with
treatment-resistant hypertension treated with RDN (mean
age 64 ± 10 years, 15 men). The total study population
could be divided into responders (n = 19) and non-re-
sponders (n = 12) following RDN. RDN reduced office
blood pressure by 18.9 ± 26.8/8.5 ± 13.5 mmHg
(p\ 0.001). A significant decrease was seen in LV pos-
terior wall thickness (LVPWd) (0.47 ± 1.0 mm;
p = 0.020), without a significant change in the LV mass
index (LVMI). In the total cohort, only peak late diastolic
filling velocity (A-wave velocity) decreased significantly
by 5.3 ± 13.2 cm/s (p = 0.044) and peak untwisting
velocity decreased significantly by 14.5 ± 28.9/s
(p = 0.025).
Conclusion RDN reduced blood pressure and significantly
improved functional myocardial parameters such as
A-wave velocity and peak untwisting velocity in patients
with treatment-resistant hypertension, suggesting a poten-
tial beneficial effect of RDN on myocardial mechanics.
Keywords Speckle tracking echocardiography  Twist 
Strain  Renal sympathetic denervation
Background
Hypertension is associated with a significantly increased
risk for adverse cardiac and cerebrovascular events, as well
as chronic kidney disease [1]. Despite optimal medical
treatment, blood pressure control often remains poor and
the risk for cardiovascular disease remains high. With
prevalence ranging between 15 and 30%, treatment-resis-
tant hypertension remains an important medical challenge
and leads to intrinsic changes in the heart muscle and is
associated with left ventricular (LV) hypertrophy and
diastolic dysfunction [2, 3].
Catheter-based renal denervation (RDN) has been
introduced as a treatment modality to optimise blood
pressure control in patients with treatment-resistant
hypertension by reducing sympathetic nerve activity.
Unfortunately, the exact blood pressure-lowering effect of
renal sympathetic denervation remains disputed, demon-
strated by non-responder rates varying between 8 and 37%,
depending on study-specific cohorts and definitions used
[4]. However, sympathetic hyperactivity has been directly
associated with LV remodelling and heart rate, which
makes it imperative to look at the effects of renal
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sympathetic denervation beyond blood pressure [5].
Speckle tracking echocardiography (STE) is a new
echocardiography modality that is able to measure LV
characteristics, including rotation, strain and strain rate.
Strain measures myocardial fibre contraction and relax-
ation [6]. This study aims to assess the effect of RDN on
functional myocardial parameters, including STE, and to
identify potential differences between responders and non-
responders.
Methods
Study population
The study population consisted of 31 consecutive patients
undergoing RDN in the context of treatment for resistant
hypertension according to recent recommendations [7].
Patients were included between December 2012 and June
2014. All patients underwent non-invasive pre-procedural
renal artery imaging and were discussed in a multi-disci-
plinary team including interventional cardiologists, radi-
ologists and hypertension specialists. As part of routine
practice, all patients referred for RDN underwent extensive
blood and urine analyses, 24-h ambulatory blood pressure
measurement (24 h ABPM), echocardiography, echocar-
diogram (ECG) and magnetic resonance imaging (MRI) to
assess renal artery eligibility and exclude renal artery
stenosis in order to be able to exclude secondary causes of
hypertension. Informed consent was obtained from all
patients.
Definitions and end-points
Office blood pressure measurements were recorded three
times in a resting situation with intervals of 5 min using an
Omron automated blood pressure monitor. Patients were
classified as responders in case the drop in 6 months office
systolic blood pressure was 10 mmHg or higher. In order to
identify subtle changes in LV function, STE was used to
obtain apical rotation, basal rotation, LV twist, twist
velocity, peak untwisting velocity, time to peak untwisting
velocity, global longitudinal strain (GLS), global circum-
ferential strain (GCS), peak early and late longitudinal
diastolic strain rate, and peak early and late circumferential
diastolic strain rate. LV twist is defined as the maximal
value of the apical systolic rotation–basal systolic rotation
[8].
Transthoracic echocardiography
Echocardiography measurements were performed before
the RDN procedure (baseline) and 6 months after the RDN
procedure. Two-dimensional grey-scale images were
obtained in the left lateral decubitus position using a
commercially available ultrasound system (iE33, Philips,
Best, The Netherlands), equipped with a broadband
(1–5 MHz) S5-1 transducer (frequency transmitted
1.7 MHz, received 3.4 MHz). Data were analysed by two
experienced echocardiographers according to the recent
recommendations [9]. The following echocardiographic
parameters were acquired: LV end-diastolic septal (LVSd)
and posterior wall thickness (LVPWd), and LV end-dias-
tolic (LVEDD) and end-systolic dimension (LVESD). LV
mass was calculated with the Devereux formula [10]. Body
surface area (BSA) was calculated according to the Mos-
teller formula [11]. LV mass was indexed by BSA as
recommended in the guidelines [12].
From the mitral inflow pattern, peak early (E-wave
velocity) and late (A-wave velocity) filling velocities, E/A
ratio and E-wave velocity deceleration time were mea-
sured. Tissue Doppler was applied end-expiratory in the
pulsed-wave Doppler mode at the level of the inferoseptal
side of the mitral annulus from an apical four-chamber
view, to obtain Em septal (peak early diastolic wave
velocity of the mitral annulus) and E/Em ratio.
To acquire the highest wall tissue velocities, the angle
between the Doppler beam and the longitudinal motion of
the investigated structure was adjusted to a minimal level.
The spectral pulsed-wave Doppler velocity range was
adjusted to obtain appropriate scale.
To optimise STE, the settings were adjusted to obtain a
frame rate of 50–70 frames/s. The echo images were
transformed to a QLAB Advanced Quantification Software
workstation (version 10.0, Philips, Best, The Netherlands)
for offline analysis.
Speckle tracking analysis
STE is an approved echocardiographic modality that
provides information on regional and global ventricular
function [13]. In order to obtain this information, apical
long-axis views (four-, three- and two-chamber views)
and parasternal short-axis views (at the apical, mid-ven-
tricular and basal LV levels) were assessed. The aortic
valve closure was assessed in a parasternal long-axis view
and added manually. After selecting the appropriate view,
the endocardial border was automatically recognised and
the tracking points were positioned. When this auto-trace
function was not optimal, the tracking points were re-
positioned manually on an end-diastolic frame. Next, the
software automatically tracked these points using speckle
tracking. LV ejection fraction was assessed using this
automated endocardial border detection. Most components
of LV systolic function [rotation (clockwise rotation as
viewed from the apical level has a positive value and
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counterclockwise rotation from the basal level has a
negative value), twist, global circumferential strain (GCS)
and GCS rate (GCSR)] and diastolic function (peak
untwisting velocity, time to peak untwisting velocity,
peak early and late circumferential diastolic strain rate)
were abstracted from parasternal short-axis views,
whereas others were derived from the apical views [sys-
tolic function: global longitudinal strain (GLS) and GLS
rate (GLSR); diastolic function: peak early and late lon-
gitudinal diastolic strain rate]. Data were exported to a
spreadsheet program (Excel, Microsoft Corporation,
Redmond, WA) to determine these parameters. In a pre-
vious study, we have demonstrated the reproducibility and
variability of the parameters investigated in the current
study in our centre [14].
RDN procedure
Procedures were performed using four different systems:
ParadiseTM (ReCor Medical, Palo Alto, CA) (n = 13),
OneShotTM (Covidien, Campbell, CA) (n = 3), Vessix
V2TM (Boston Scientific, Natick, MA) (n = 5) and Sym-
plicityTM (Medtronic, Minneapolis, MN) (n = 10). Proce-
dures were performed according to the device-specific
instructions for use [7, 15]. All procedures were performed
under conscious sedation with midazolam and fentanyl.
Statistical analysis
All continuous variables are expressed as mean ± stan-
dard deviation (SD). Continuous variables were compared
using Student’s t test. Simple linear regression of peak
untwisting velocity against heart rate was performed.
Categorical variables were compared with the Chi square
test or Fisher’s exact test when appropriate. A p-value
\0.05 was considered statistically significant. The statis-
tical analysis was performed with SPSS software (version
21.0).
Results
Study population
Thirty-one patients with resistant hypertension following
RDN were enrolled in this study, all of whom completed
the 6 months follow-up period. The mean age was
64 ± 10 years and 15 patients (48%) were male. A total of
19 patients were classified as responders versus 12 non-
responders. Besides a significantly lower age of the
responders (61 ± 10 vs. 69 ± 9 years in the non-respon-
ders; p = 0.028), no significant differences in patient
characteristics were seen between both groups (Table 1).
Blood pressure
A significant decrease was seen in office-based systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
after RDN at 6 months follow-up: 182 ± 18 vs. 163 ±
27 mmHg (p\ 0.001) and 94 ± 16 vs. 85 ± 14 mmHg
(p = 0.001), respectively. The same applied for the sys-
tolic 24 h ABPM after RDN (150 ± 12 vs. 142 ±
18 mmHg; p = 0.017) and the diastolic 24 h ABPM after
RDN (83 ± 13 vs. 78 ± 11 mmHg; p = 0.006) (Table 2).
Conventional echocardiography and STE
In the total cohort, significant differences at baseline versus
the 6-month follow-up period were noted in LVPWd,
A-wave velocity and peak untwisting velocity. LVPWd
decreased significantly from 8.8 ± 1.4 mm at baseline to
8.3 ± 1.5 mm at follow-up (p = 0.020). LV mass index
(MI) reduced by 3.2 ± 11.6 g/m2 at 6 months. A-wave
velocity decreased significantly from 69.7 ± 14.2 cm/s at
baseline to 64.4 ± 14.0 cm/s at follow-up (p = 0.044). No
significant changes were seen in the other conventional
echocardiographic parameters. Furthermore, peak untwist-
ing velocity decreased significantly from -70 ± 28.5/cm
at baseline to -56 ± 24.9/cm at follow-up (p = 0.025)
(Table 2).
Stratifying the cohort in responders and non-responders
did reveal significant changes from baseline to follow-up in
A-wave velocity and peak untwisting velocity in the
responders (Fig. 1). In the non-responders, LVESD
increased significantly from 37.4 ± 9.3 to 39.7 ± 10.1 mm
(p = 0.013), although it should be noted that LV ejection
fraction (EF) showed no difference. Also, no differences
were found in the more sensitive systolic parameters GLS,
GCS and LV twist.
Comparing the baseline characteristics of both cohorts,
no difference was observed in the LVMI at baseline in the
responders as compared to the non-responders (98 ± 25.4
vs. 116 ± 42.9 g/m2) (Table 3).
Predictors for response
No association was found between the clinical character-
istics, conventional echocardiographic and speckle tracking
parameters which could predict response.
Discussion
The aim of this study was to assess if RDN resulted in
functional and structural cardiac changes as assessed using
both conventional 2D echocardiography and 2D STE. A
secondary objective was to assess any differences in these
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parameters between responders and non-responders. We
observed a significant difference in blood pressure and
heart rate at 6 months post procedure. Echocardiographi-
cally, at 6 months, a significant difference was noted in
LVPWd and A-wave velocity. Additionally, STE
demonstrated a significant difference in peak untwisting
velocity.
Persistent sympathetic nervous system hyperactivity
plays a critical role in hypertension and is associated with
significant structural and functional cardiac changes [16].
In this study, we found that RDN significantly reduced
office blood pressure by 18.9 ± 26.8/8.5 ± 13.5 mmHg
(p\ 0.001) and heart rate by 4.5 ± 9.9 beats/min
(p = 0.016). In line with these findings, we observed a
significant decrease in LVPWd (0.47 ± 1.0 mm), along
with a reduction in LVMI of 3.2 ± 11.6 g/m2 in the total
cohort. The fact that this reduction did not reach statistical
significance could be due to a lack of power.
Looking further into diastolic function, which is strongly
related to hypertension and blood pressure control,
revealed a pseudonormal diastolic dysfunction, based on
normal E/A ratio, but increased left atrial (LA) dimension
and E/Em ratio in the overall study population. We
observed a significant decrease in the A-wave velocity by
5.3 ± 13.2 cm/s (p = 0.044) in the total population. In the
responders, the difference in the A-wave velocity even
decreased to 8.5 ± 13.8 cm/s (p = 0.027). The decrease in
A-wave velocity after renal denervation could implicate an
improvement in the LV relaxation and a subsequent better
diastolic function [17]. Additionally, a pseudonormal
diastolic function may reflect a decrease in LV compliance
and a moderate increase in LA pressure in our population,
with impaired relaxation and prolonged A-wave velocity
before treatment. The link between peak untwisting
velocity and A-wave velocity may be explained by the rate
of uncoiling. In other words, it is likely that less force is
Table 1 Clinical characteristics of the study population, responder vs. non-responder at baseline
All patients Responder Non-responder p-Value
Baseline (n = 31) Baseline (n = 19) Baseline (n = 12) Responder vs.
non-responder
Age (years) 64 ± 10 61 ± 10 69 ± 9 0.028
Male gender, n (%) 15 (48) 10 (53) 5 (42) 0.552
BMI (kg/m2) 29 ± 4 29 ± 5 28 ± 3 0.639
Mean office SBP (mmHg) 182 ± 18 186 ± 20 176 ± 15 0.133
Mean office DBP (mmHg) 94 ± 16 97 ± 14 89 ± 18 0.149
Mean systolic ABPM (mmHg) 150 ± 12 148 ± 12 152 ± 13 0.358
Mean diastolic ABPM (mmHg) 83 ± 13 83 ± 11 82 ± 17 0.946
Heart rate (beats/min) 68 ± 12 69 ± 12 65 ± 12 0.282
CAD (%) 16 (52) 12 (63) 4 (33) 0.106
Atrial fibrillation (%) 2 (7) 2 (11) – 0.368
Cardiovascular risk factors, n (%)
Hypercholesterolaemia 22 (71) 15 (79) 7 (58) 0.204
Current smoker 11 (36) 6 (32) 5 (42) 0.619
Diabetes mellitus 8 (26) 7 (37) 1 (8) 0.086
Number of hypertensive drugs 4 ± 1 4 ± 1 4 ± 1 0.634
Patients receiving (drug class) (%)
ACE inhibitors/ARBs 27 (87) 17 (90) 10 (83) 0.507
Direct renin inhibitors 1 (3) – 1 (8) 0.387
Beta-blockers 25 (81) 16 (84) 9 (75) 0.435
Alpha-blockers 9 (29) 4 (21) 5 (42) 0.168
Calcium channel blockers 25 (81) 16 (84) 9 (75) 0.435
Aldosterone antagonist 4 (13) 3 (16) 1 (8) 0.493
Diuretics 22 (71) 13 (68) 9 (75) 0.417
Central acting agent 3 (10) 1 (5) 2 (17) 0.328
Values are mean ± standard deviation (SD) or n (%)
BMI Body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; ABPM ambulatory blood pressure monitoring; CAD coronary
artery disease; ACE angiotensin-converting enzyme; ARBs angiotensin receptor blocker
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Table 2 Clinical,
echocardiographic and speckle
tracking parameters in patients
following renal denervation
Baseline Follow-up (6 months) p-Value
Clinical parameters
Mean office SBP (mmHg) 182 ± 18 163 ± 27 \0.001
Mean office DBP (mmHg) 94 ± 16 85 ± 14 0.001
Mean systolic ABPM (mmHg) 150 ± 12 142 ± 18 0.017
Mean diastolic ABPM (mmHg) 83 ± 13 78 ± 11 0.006
Heart rate (beats/min) 68 ± 12 63 ± 11 0.016
Echocardiographic parameters
LA size (mm) 45.1 ± 7.9 44.5 ± 6.8 0.523
LAVI (mL/m2) 36.8 ± 10.9 35.6 ± 11.0 0.335
IVSd (mm) 10.8 ± 2.1 10.3 ± 1.8 0.105
LVPWd (mm) 8.8 ± 1.4 8.3 ± 1.5 0.020
LVEDD (mm) 53.8 ± 8.1 55.5 ± 7.9 0.028
LVESD (mm) 37.7 ± 8.7 39.5 ± 8.3 0.048
LVEF (%) 59.5 ± 11.0 58.1 ± 10.1 0.123
LVMI (g/m2) 105.8 ± 33.8 102.6 ± 30.2 0.133
Doppler indices
E (cm/s) 67.2 ± 20.5 65.0 ± 23.1 0.519
A (cm/s) 69.7 ± 14.2 64.4 ± 14.0 0.044
E/A ratio 1.0 ± 0.3 1.0 ± 0.4 0.557
DET (ms) 219.7 ± 51.6 219.7 ± 84.3 0.996
Em septal (cm/s) 5.5 ± 1.8 5.1 ± 1.7 0.134
E/Em ratio 12.3 ± 4.7 12.5 ± 3.0 0.840
Speckle tracking echocardiography
GLS (%) -19.6 ± 4.2 -19.9 ± 3.5 0.653
GCS (%) -27.3 ± 6.5 -27.2 ± 5.3 0.877
Early GLSR 0.89 ± 0.25 0.89 ± 0.21 0.932
Late GLSR 0.80 ± 0.23 0.82 ± 0.24 0.495
Early GCSR 1.88 ± 0.62 1.80 ± 0.51 0.470
Late GCSR 1.39 ± 0.50 1.32 ± 0.44 0.432
Apical GR () 4.8 ± 3.4 4.3 ± 2.7 0.542
Basal GR () -4.2 ± 2.0 -3.5 ± 2.2 0.212
Twist () 8.7 ± 4.4 7.4 ± 3.7 0.178
Twist velocity (/s) 15.5 ± 12.9 13.7 ± 12.1 0.665
Peak untwisting velocity (/s) -70.6 ± 28.5 -56.1 ± 24.9 0.025
Time to peak untwisting velocity (s) 0.08 ± 0.07 0.09 ± 0.08 0.707
LVEDV (mL) 76.1 ± 28.4 82.6 ± 34.2 0.152
LVESV (mL) 30.5 ± 17.9 33.9 ± 22.9 0.146
LVEF (%) 61.8 ± 10.1 61.5 ± 8.5 0.803
Values are mean ± SD
SBP Systolic blood pressure; DBP diastolic blood pressure; ABPM ambulatory blood pressure monitoring;
LA left atrial; LAVI left atrial volume indexed; IVSd interventricular septum thickness (diastole); LVPWd
left ventricular posterior wall thickness (diastole); LVEDD left ventricular end-diastolic dimension; LVESD
left ventricular end-systolic dimension; LVEF left ventricular ejection fraction; LVMI left ventricular mass
index; E peak early phase filling velocity; A peak atrial phase filling velocity; DET deceleration time; Em
peak early wave velocity; GLS global longitudinal strain; GCS global circumferential strain; GLSR global
longitudinal strain rate (early and late diastole); GCSR global circumferential strain rate (early and late
diastole); GR global rotation (apical and basal level). Twist is defined as the instantaneous left ventricular
peak systolic twist. The peak untwisting velocity is the peak diastolic de-rotation velocity. EDV End-
diastolic volume; ESV end-systolic volume
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needed for the active atrial contraction during late diastolic
filling after blood pressure lowering. The relation between
LV untwisting and the conventional parameters was also
described in previous work, in which a positive correlation
between untwisting rate and A-wave velocity was found,
while there was no correlation between E-wave velocity
and untwisting rate [8]. However, these findings should be
interpreted with caution, as no differences were noted in
other echocardiographic parameters determining diastolic
function, such as the E/Em ratio and LA dimensions.
Hypertensive patients have a greater risk of develop-
ing cardiac fibrosis, myocyte hypertrophy and diastolic
dysfunction [18]. These changes may influence the LV
twist and rotation [19]. LV twist is a wringing motion of
the heart as the apex rotates with respect to the base
around the LV long axis, which is a key element for
regulating LV systolic and diastolic mechanics [20]. LV
twist is derived from the dynamic interaction between
subendocardial and subepicardial myocardial fibres, the
latter defining the direction of the LV twist. It is known
that, in myocardial fibrosis and LV hypertrophy, which
is related to pressure overload, impairment appears fre-
quently in the subendocardial layer, leading to a domi-
nance of the subepicardial fibres [21]. This might explain
the increased LV twist in patients with LV hypertrophy.
LV untwisting starts after the peak LV twist. In a
healthy population, the peak systolic twist is supposed to
store potential energy and is thought to contribute
towards diastolic suction and facilitate early LV diastolic
filling. Previous work from our group demonstrated that
peak untwisting velocity is increased in hypertrophic
cardiomyopathy patients with mild diastolic dysfunction,
as well as in aortic stenosis patients [8, 22]. Our study is
the first to demonstrate a significant decrease in peak
untwisting velocity of 14.5 ± 28.9/s (p = 0.025) in
patients undergoing RDN. This change was mainly dri-
ven by a change in peak untwisting velocity by
24.1 ± 28.7/s (p = 0.006) in the responders. In non-
responders, no difference following RDN was observed.
The decrease in untwisting velocity after renal dener-
vation could implicate an improvement in the LV
relaxation and a subsequent better diastolic function,
similar to A-wave velocity. One may hypothesise that, in
hypertension patients, like in hypertrophic cardiomy-
opathy and aortic stenosis patients, increased peak
untwisting velocity serves as a compensatory mechanism
for abnormal relaxation and prevents the need to
increase LA pressure [22, 23]. RDN probably leads to an
improvement of these specific changes in LV rotational
and de-rotational mechanics, especially in responders.
However, no significant change was seen in twist and
twist velocity. Finally, we observed a significant
decrease in heart rate following RDN in our population.
This is in line with several randomised controlled studies
which also demonstrated a decrease in heart rate fol-
lowing RDN [24, 25]. Interestingly, a similar decrease in
heart rate was observed in the (sham) control arm of
both studies, suggesting that RDN by itself has no sig-
nificant effect on heart rate. Additional exploratory
analyses in our study ruled out a correlation between
heart rate and untwisting velocity (R2 = 0.1%).
Future studies, comparing hypertensive patients with a
healthy control group, may be warranted in order to
investigate myocardial geometry changes in hypertensive
subjects in the context of diastolic LV twisting and
untwisting, blood pressure or heart rate independently.
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Limitations
Data are derived from a small patient population and a lack of
power might have impacted our findings. Furthermore, accu-
rate assessment of changes in cardiac systolic and diastolic
function and volumes with conventional echocardiography
produces limited image quality in patients with a body mass
index (BMI) above 25 kg/m2. In some patients (n = 6),
automatically detected LV contours had be corrected manu-
ally, which might have impacted the reliability of the mea-
surements. Four different renal denervation systems were
used.Based on individual previous studies, the bloodpressure-
lowering effect of these individual devices remains in the same
range; however, a differential effect on the echocardiographic
parameters measured in our study could not be excluded.
Conclusion
Renal sympathetic denervation (RDN) reduced blood
pressure and heart rate, and significantly improved func-
tional myocardial parameters such as A-wave velocity and
Table 3 Baseline and 6-month follow-up parameters in patients following renal denervation, responders vs. non-responders
Responder (n = 19) Non-responder (n = 12) p value
Baseline 6 months p value Baseline 6 months p value Responder vs.
non-responder
at baseline
Echocardiographic parameters
LA size (mm) 44.6 ± 8.0 44.2 ± 7.5 0.712 45.8 ± 7.9 44.9 ± 5.7 0.585 0.706
LAVI (mL/m2) 37.3 ± 11.1 36.0 ± 12.2 0.394 36.1 ± 11.3 34.9 ± 9.7 0.637 0.855
IVSd (mm) 10.5 ± 2.0 10.3 ± 2.2 0.408 11.3 ± 2.2 10.3 ± 1.2 0.176 0.352
LVPWd (mm) 8.7 ± 1.6 8.3 ± 1.8 0.130 9.0 ± 1.2 8.4 ± 1.2 0.089 0.546
LVEDD (mm) 52.9 ± 7.8 55.1 ± 6.8 0.060 55.1 ± 8.7 56.2 ± 9.7 0.289 0.484
LVESD (mm) 37.9 ± 8.5 39.4 ± 7.3 0.284 37.4 ± 9.3 39.7 ± 10.1 0.013 0.872
LVEF (%) 57.6 ± 10.1 57.0 ± 9.5 0.587 62.5 ± 12.2 59.8 ± 11.1 0.088 0.235
LVMI (g/m2) 98.8 ± 25.4 98.8 ± 25.4 a 116 ± 42.9 108.5 ± 36.9 0.136 0.151
Doppler indices
E (cm/s) 72.2 ± 19.5 70.9 ± 24.7 0.759 59.7 ± 20.5 56.2 ± 17.7 0.555 0.103
A (cm/s) 69.9 ± 17.0 61.4 ± 14.4 0.027 69.3 ± 10.0 68.4 ± 13.0 0.785 0.914
E/A ratio 1.0 ± 0.3 1.1 ± 0.3 0.374 0.9 ± 0.3 0.9 ± 0.4 0.889 0.249
DET (ms) 207.5 ± 40.6 189.7 ± 41.7 0.155 238.1 ± 62.2 264.6 ± 111.3 0.400 0.113
Em septal (cm/s) 5.6 ± 1.6 5.3 ± 1.7 0.515 5.5 ± 2.1 4.8 ± 1.8 0.151 0.882
E/Em ratio 12.5 ± 3.6 12.5 ± 3.3 0.872 12.2 ± 5.8 12.3 ± 2.9 0.898 0.875
Speckle tracking echocardiography
Twist () 8.0 ± 3.8 6.8 ± 3.8 0.242 10.1 ± 5.2 8.6 ± 3.5 0.492 0.278
Twist velocity (/s) 14.7 ± 13.2 13.3 ± 11.2 0.792 17.1 ± 13.2 14.5 ± 14.5 0.740 0.673
Peak untwisting velocity (/s) -73.8 ± 30.4 -49.7 ± 23.8 0.006 -64.6 ± 25.5 -68.2 ± 23.5 0.637 0.475
Time to peak untwisting velocity (s) 0.07 ± 0.08 0.09 ± 0.08 0.431 0.10 ± 0.06 0.08 ± 0.07 0.509 0.389
GLS (%) -19.2 ± 4.7 -19.5 ± 3.9 0.661 -20.6 ± 3.0 -20.6 ± 2.4 0.938 0.480
GCS (%) -27.2 ± 6.7 -26.5 ± 5.9 0.476 -27.5 ± 6.5 -28.5 ± 4.2 0.657 0.916
Early GLSR 0.90 ± 0.28 0.89 ± 0.19 0.809 0.87 ± 0.21 0.91 ± 0.26 0.460 0.625
Late GLSR 0.76 ± 0.25 0.77 ± 0.24 0.840 0.86 ± 0.19 0.92 ± 0.22 0.429 0.188
Early GCSR 1.91 ± 0.56 1.81 ± 0.50 0.339 1.81 ± 0.75 1.77 ± 0.57 0.883 0.736
Late GCSR 1.26 ± 0.53 1.15 ± 0.33 0.320 1.62 ± 0.34 1.62 ± 0.48 0.990 0.094
Values are mean ± SD
LA Left atrial; LAVI left atrial volume index; IVSd interventricular septum thickness (diastole); LVPWd left ventricular posterior wall thickness
(diastole); LVEDD left ventricular end-diastolic dimension; LVESD left ventricular end-systolic dimension; LVEF left ventricular ejection
fraction; LVMI left ventricular mass index; E peak early phase filling velocity; A peak atrial phase filling velocity; DET deceleration time; Em
peak early wave velocity. Twist is defined as the instantaneous left ventricular peak systolic twist. The peak untwisting velocity is the peak
diastolic de-rotation velocity. GLS Global longitudinal strain; GCS global circumferential strain; GLSR global longitudinal strain rate (early and
late diastole); GCSR global circumferential strain rate (early and late diastole)
a Standard error of the difference
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peak untwisting velocity in patients with treatment-resis-
tant hypertension, suggesting potential pleiotropic benefi-
cial effects of renal sympathetic denervation on myocardial
mechanics. Further dedicated studies are needed to eluci-
date the potential role of RDN on echocardiographic
parameters.
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